Lancet Diab & Endo:依帕列净二线降糖不劣于格列美脲

2014-07-18 伊文 中华医学会糖尿病学分会

近期发表的一项为期104周的随机、活性药物对照、双盲、Ⅲ期临床研究表明,在2型糖尿病患者中,当二甲双胍治疗失败时,加用SGLT2抑制剂依帕列净对HbA1c的降低效果不劣于加用格列美脲。两种联用策略的不良反应和严重不良反应发生率均无显著差异,依帕列净组的低血糖事件发生率明显低于格列美脲组(2% vs 24%)。 原始出处: Ridderstråle M

近期发表的一项为期104周的随机、活性药物对照、双盲、Ⅲ期临床研究表明,在2型糖尿病患者中,当二甲双胍治疗失败时,加用SGLT2抑制剂依帕列净对HbA1c的降低效果不劣于加用格列美脲。两种联用策略的不良反应和严重不良反应发生率均无显著差异,依帕列净组的低血糖事件发生率明显低于格列美脲组(2% vs 24%)。

原始出处:

Ridderstråle M1, Andersen KR2, Zeller C3, Kim G4, Woerle HJ4, Broedl UC4; on behalf of the EMPA-REG H2H-SU trial investigators.Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.Lancet Diabetes Endocrinol. 2014 Jun 16. pii: S2213-8587(14)70120-2. doi: 10.1016/S2213-8587(14)70120-2. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=20693, encodeId=3eec2069330, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:31:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636914, encodeId=dafd163691447, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 19 08:46:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827841, encodeId=02cd182e84180, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 13 00:46:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417281, encodeId=aaf3141e28122, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Sun Jul 20 01:46:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2015-04-11 x35042875

    糖尿病肾病进展风险的关系没有发现。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=20693, encodeId=3eec2069330, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:31:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636914, encodeId=dafd163691447, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 19 08:46:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827841, encodeId=02cd182e84180, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 13 00:46:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417281, encodeId=aaf3141e28122, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Sun Jul 20 01:46:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=20693, encodeId=3eec2069330, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:31:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636914, encodeId=dafd163691447, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 19 08:46:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827841, encodeId=02cd182e84180, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 13 00:46:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417281, encodeId=aaf3141e28122, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Sun Jul 20 01:46:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2015-01-13 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=20693, encodeId=3eec2069330, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:31:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636914, encodeId=dafd163691447, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 19 08:46:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827841, encodeId=02cd182e84180, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 13 00:46:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417281, encodeId=aaf3141e28122, content=<a href='/topic/show?id=266826884bf' target=_blank style='color:#2F92EE;'>#依帕列净#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26884, encryptionId=266826884bf, topicName=依帕列净)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0353248055, createdName=DEXTER3140, createdTime=Sun Jul 20 01:46:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]

相关资讯

Diabetes Obes Metab:依帕列净多重功效获新证据

近期发表的一项囊括10项随机对照研究的Meta分析表明,对于2型糖尿病患者,与安慰剂相比,钠葡萄糖共同转运蛋白2(SGLT-2)抑制剂依帕列净(empagliflozin)除了能有效降低血糖外,还有助于减轻体重和降低血压。(Diabetes Obes Metab. 2014年4月26日在线版)在该分析中,依帕列净以10 mg或25 mg应用对HbA1c水平的降低效果均显著优于安慰剂,其中25 mg